Immix Biopharma (IMMX) Appoints Michaela Liedtke to its Scientific Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford University Medical CenterDr. Liedtke is a recognized thought leader in.
Successful completion supports expansion of its ongoing NEXICART-1 NXC-201 CAR-T clinical trial to the U.S.NXC-201 is manufactured at our state-of-the-art cellular immunotherapy manufacturing.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) is one of 888 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Immix Biopharma to related businesses based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings. Volatility and Risk […]